Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies

Lancet Oncol. 2015 Jun;16(6):e293-302. doi: 10.1016/S1470-2045(14)71206-9. Epub 2015 May 27.

Abstract

Arguably, nowhere has there been a greater advance in our understanding of biological mechanisms and potential translational targets during the next-generation sequencing era than in paediatric brain tumours. The so-called omics revolution, enabled by high-throughput sequencing, has empowered large consortia and independent groups alike to make major genetic discoveries, from dominant-negative histone mutations and hijacking of distal enhancer elements, to new oncogenic gene fusions and aberrantly active gene expression. Epigenetic deregulation has also been revealed as a common theme across several tumour subtypes. This Review focuses on key findings that have been transforming the landscape of paediatric neuro-oncology research and how these results are opening new avenues towards potential therapeutic translation.

Publication types

  • Review

MeSH terms

  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / genetics
  • Brain Neoplasms / pathology
  • Child
  • DNA Methylation / genetics
  • Gene Expression Regulation, Neoplastic
  • Gene Fusion
  • High-Throughput Nucleotide Sequencing*
  • Humans
  • Medulloblastoma / drug therapy*
  • Medulloblastoma / genetics
  • Medulloblastoma / pathology
  • Molecular Targeted Therapy*
  • Neoplasm Proteins / biosynthesis

Substances

  • Neoplasm Proteins